Taysha Gene Therapies (NASDAQ:TSHA) PT Lowered to $32.00 at Chardan Capital – Defense World

Taysha Gene Therapies (NASDAQ:TSHA Get Rating) had its price target cut by Chardan Capital from $34.00 to $32.00 in a research note published on Friday, Marketbeat reports. They currently have a buy rating on the stock.

TSHA has been the subject of a number of other reports. Wedbush reduced their price target on shares of Taysha Gene Therapies from $9.00 to $5.00 and set an outperform rating for the company in a report on Friday. The Goldman Sachs Group lowered their price objective on shares of Taysha Gene Therapies from $27.00 to $16.00 and set a buy rating on the stock in a research report on Tuesday, May 24th. Guggenheim reduced their target price on shares of Taysha Gene Therapies to $22.00 and set a na rating for the company in a research note on Tuesday, May 17th. Finally, Needham & Company LLC reduced their price objective on shares of Taysha Gene Therapies to $20.00 and set a buy rating for the company in a research note on Tuesday, May 17th. Twelve investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of Buy and an average target price of $27.08.

Shares of NASDAQ:TSHA opened at $4.10 on Friday. The companys 50 day moving average price is $3.95 and its two-hundred day moving average price is $4.90. Taysha Gene Therapies has a 12-month low of $2.33 and a 12-month high of $21.90. The firm has a market cap of $166.24 million, a PE ratio of -0.85 and a beta of 0.99. The company has a quick ratio of 2.20, a current ratio of 2.20 and a debt-to-equity ratio of 0.74.

In other Taysha Gene Therapies news, CMO Suyash Prasad sold 23,923 shares of Taysha Gene Therapies stock in a transaction dated Friday, July 1st. The stock was sold at an average price of $3.53, for a total value of $84,448.19. Following the transaction, the chief marketing officer now owns 543,450 shares in the company, valued at $1,918,378.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 40,152 shares of company stock worth $145,109 over the last three months. 42.40% of the stock is owned by corporate insiders.

Large investors have recently bought and sold shares of the stock. 683 Capital Management LLC acquired a new position in shares of Taysha Gene Therapies during the 4th quarter worth approximately $117,000. ProShare Advisors LLC acquired a new position in Taysha Gene Therapies during the 4th quarter worth about $121,000. Sargent Investment Group LLC acquired a new stake in Taysha Gene Therapies in the 1st quarter valued at about $69,000. Virtus ETF Advisers LLC raised its position in Taysha Gene Therapies by 39.3% in the 4th quarter. Virtus ETF Advisers LLC now owns 11,519 shares of the companys stock valued at $134,000 after purchasing an additional 3,251 shares in the last quarter. Finally, Nisa Investment Advisors LLC acquired a new stake in Taysha Gene Therapies in the 1st quarter valued at about $129,000. 46.05% of the stock is owned by institutional investors and hedge funds.

(Get Rating)

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.

Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Read more:
Taysha Gene Therapies (NASDAQ:TSHA) PT Lowered to $32.00 at Chardan Capital - Defense World